Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer

Executive Summary

Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.

You may also be interested in...



Boehringer Bigs Up US and China As Europe Sales Slip

Away from the pricing pressures, reimbursement battles and problems of patent expiries in its home continent, the German major is counting on the US and China to provide the best opportunities for future growth.

Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

The Swiss major has made a larger-than-expected bolt-on buy, using a large chunk of its $13bn windfall from GSK to get hold of a potential cure for spinal muscular atrophy and an additional gene therapy platform, as well as manufacturing capabilities.

Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing

Solid Biosciences was able to launch an IPO earlier this year despite a last minute disclosure about a partial clinical hold, which is now a full clinical hold that's cost investors money. Even so, Arcus Biosciences was able to launch its IPO. Ideaya, JW lead recent VC financings.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC122876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel